raremaprare-disease reference indexOrphadata 2026-06-23 · HPO 2026-09-01
ORPHA:99757

Embryonal rhabdomyosarcoma

Type
Clinical subtype
Group
Subtype of disorder
Inheritance
Multigenic/multifactorial
Status
active

This disease is described under Rhabdomyosarcoma

1

Names in Orphadata languages

12 of 12 languages
LangNameSynonyms
enEmbryonal rhabdomyosarcoma
frRhabdomyosarcome embryonnaire
deRhabdomyosarkom, embryonales
esRabdomiosarcoma embrionario
itRabdomiosarcoma embrionale
nlEmbryonaal rhabdomyosarcoom
ptRabdomiossarcoma, embrionário
plMięsak prążkowanokomórkowy płodowy
csEmbryonální rhabdomyosarkom
ukЕмбріональна рабдоміосаркома
zh胚胎横纹肌肉瘤
trEmbriyonal rabdomyosarkom
2

Cross-references

qualifier = Orphanet mapping relation
SourceCodeQualifierICD relationValidation
OMIM180295BTNTvalidated
OMIM268210BTNTvalidated
ICD-10C49.9NTBTindexvalidated
MONDO0009993Evalidated
MeSHD018233Evalidated
UMLSC0206656Evalidated
GARD4702Evalidated
MedDRA10065868Evalidated

E exact · NTBT this ORPHAcode is narrower than the target · BTNT broader than the target · ND not decided.

3

Classification

Preferential parent (Orphanet linearisation):

Parents in the classifications (1):

No children.

4

Genes

4 direct
GeneAssociationStatusHGNCEnsemblOMIMLocusNameSource of validation
SLC67A1Candidate gene tested inNot yet assessedHGNC:10964ENSG0000011062860263111p15.4solute carrier family 67 member 19520460[PMID]
TP53Disease-causing germline mutation(s) inAssessedHGNC:11998ENSG0000014151019117017p13.1tumor protein p537706467[PMID]
DICER1Disease-causing somatic mutation(s) inAssessedHGNC:17098ENSG0000010069760624114q32.13dicer 1, ribonuclease III22180160[PMID]
NF1Disease-causing somatic mutation(s) inAssessedHGNC:7765ENSG0000019671261311317q11.2neurofibromin 134166060[PMID]
5

Prevalence and incidence

23 records
TypeClassValueAreaQualificationValidationSource
Annual incidence<1 / 1 000 0000.048 / 100 000AustriaValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence<1 / 1 000 0000.091 / 100 000BelgiumValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence<1 / 1 000 0000.034 / 100 000BulgariaValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence<1 / 1 000 0000.054 / 100 000CroatiaValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence<1 / 1 000 0000.011 / 100 000Czech RepublicValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence<1 / 1 000 0000.055 / 100 000EstoniaValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence<1 / 1 000 0000.005 / 100 000FinlandValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence<1 / 1 000 0000.046 / 100 000GermanyValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence<1 / 1 000 0000.089 / 100 000IrelandValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence<1 / 1 000 0000.045 / 100 000ItalyValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence<1 / 1 000 0000.032 / 100 000LatviaValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence<1 / 1 000 0000.046 / 100 000LithuaniaValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence<1 / 1 000 0000.057 / 100 000NorwayValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence<1 / 1 000 0000.035 / 100 000PolandValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence<1 / 1 000 0000.051 / 100 000PortugalValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence<1 / 1 000 0000.074 / 100 000SlovakiaValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence<1 / 1 000 0000.088 / 100 000SloveniaValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence<1 / 1 000 0000.051 / 100 000SpainValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence<1 / 1 000 0000.051 / 100 000SwitzerlandValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence<1 / 1 000 0000.093 / 100 000NetherlandsValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence<1 / 1 000 0000.053 / 100 000United KingdomValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence1-9 / 1 000 0000.128 / 100 000IcelandValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence1-9 / 1 000 0000.126 / 100 000MaltaValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]

Value is Orphadata's ValMoy: the mean estimate per 100 000 for prevalence and incidence, the number of cases or families for case reports.

6

HPO phenotypes

Orphanet has no HPO annotation for this code in this release.

7

Sources for this card